Novartis taps Molecular Partners for a novel approach to combat COVID-19 Novartis is spending USD 69 million upfront on a pair of experimental drugs from Molecular Partners. The pact is for MP0420 and MP0423, two antivirals out of the biotech’s so-called DARPin tech, which Molecular Partners says that it has ...
Find MoreThe American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.